Posters and Publications
Scientific Presentations and Publications
Edgewise presents original research on its science and therapeutic development at scientific and medical conferences, as well as in published peer-reviewed scientific journals.
Please contact us if you would like to learn more about the research presented here.
June 2022
EDG-5506: A Novel Approach to Protect Muscle in Duchenne Muscular Dystrophy
2022 PPMD Annual Conference
June 2022
EDG-5506: A Novel Approach to Protect Muscle in Becker Muscular Dystrophy
2022 PPMD Annual Conference
June 2022
Insights into the Becker Muscular Dystrophy Experience from the Duchenne Registry, a Comprehensive Registry for Duchenne and Becker Muscular Dystrophy
2022 PPMD Annual Conference
June 2022
EDG-5506: A Novel Approach to Protect Muscle in Duchenne and Becker Muscular Dystrophy
2022 PPMD Annual Conference
June 2022
Understanding the Becker Muscular Dystrophy (BMD) Experience from the Patient Perspective: It’s More Than Mild Duchenne
2022 PPMD Annual Conference
June 2022
Taking a New Approach to Protect Muscle in Duchenne and Becker Muscular Dystrophy: EDG-5506
New Directions Biology and Disease of Skeletal Muscle Conference
June 2022
Use of an Exercise Challenge System to Define a Universal Proteomic Signature of Muscle Injury in a Diverse Set of Adult Individuals with Inherited Myopathy
New Directions Biology and Disease of Skeletal Muscle Conference 2022
June 2022
Short-Term Proteomic Responses to the Fast Skeletal Myosin Inhibitor EDG-5506 in Becker Muscular Dystrophy
New Directions Biology and Disease of Skeletal Muscle Conference 2022
June 2022
EDG-5506 is a Selective Inhibitor of Fast Skeletal Muscle Myosin
New Directions Biology and Disease of Skeletal Muscle Conference 2022
June 2022
Skeletal myosin inhibitor EDG-5506 protects dystrophic muscle from contraction induced injury
New Directions Biology and Disease of Skeletal Muscle Conference 2022
May 2022
Manipulating the Dark Side of Muscle Adaptation for Therapeutic Gain
13th Annual GoldLab Symposium
March 2022
EDG 5506 Targets Fast Skeletal Myosin to Protect Dystrophic Muscle and Reduce Muscle Damage Biomarkers in a Phase 1 Trial in Becker Muscular Dystrophy
2022 MDA Clinical and Scientific Conference
March 2022
EDG-5506 Targets Fast Skeletal Myosin to Protect Dystrophic Muscle and Reduce Muscle Damage Biomarkers in a Phase 1 Trial in Becker Muscular Dystrophy
2022 MDA Clinical and Scientific Conference
March 2022
Modulating fast skeletal muscle contraction as a novel therapeutic strategy for muscular dystrophy
2022 MDA Clinical and Scientific Conference
March 2022
Use of an exercise challenge system to define a universal proteomic signature of muscle injury in a diverse set of adult individuals with inherited myopathy
2022 MDA Clinical and Scientific Conference
March 2022
A Novel Approach to Protecting Dystrophic Muscle by Targeting Fast Muscle Myosin: EDG-5506
2022 MDA Clinical and Scientific Conference
February 2022
Direct and Selective Myosin-Inhibition Stabilizes the Super-Relaxed State of Myosin and Blunts Post-Tetanic Potentiation in Fast-Skeletal Muscle
2022 Annual Meeting of the Biophysical Society
June 2021
Selective Inhibition of Fast Skeletal Muscle Myosin as a Novel Therapeutic Strategy for Muscular Dystrophy
2021 New Directions in Biology and Disease of Skeletal Muscle Conference
June 2021
Development of a Novel Therapeutic for Duchenne, Becker and other Muscular Dystrophies
2021 PPMD Annual Conference
May 2021
Elevation of fast but not slow troponin I in the circulation of patients with Becker and Duchenne muscular dystrophy
Muscle & Nerve, March 8, 2021